Our top pick for
Genpact Limited is an information technology services business based in the US. Genpact shares (G) are listed on the NYSE and all prices are listed in US Dollars. Genpact employs 104,000 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$50.56|
|52-week range||$33.59 - $52.64|
|50-day moving average||$49.37|
|200-day moving average||$47.55|
|Wall St. target price||$52.59|
|Dividend yield||$0.41 (0.83%)|
|Earnings per share (TTM)||$1.82|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-13)||4.90%|
|1 month (2021-09-20)||4.31%|
|3 months (2021-07-20)||4.98%|
|6 months (2021-04-20)||13.06%|
|1 year (2020-10-20)||35.37%|
|2 years (2019-10-18)||29.38%|
|3 years (2018-10-19)||75.80%|
|5 years (2016-10-20)||114.78%|
Valuing Genpact stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Genpact's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Genpact's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 27x. In other words, Genpact shares trade at around 27x recent earnings.
That's comparable to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29).
Genpact's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.7. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Genpact's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Genpact's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $682.9 million.
The EBITDA is a measure of a Genpact's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$3.8 billion|
|Operating margin TTM||13.69%|
|Gross profit TTM||$1.3 billion|
|Return on assets TTM||6.71%|
|Return on equity TTM||20.25%|
|Market capitalisation||$9.4 billion|
TTM: trailing 12 months
There are currently 3.6 million Genpact shares held short by investors – that's known as Genpact's "short interest". This figure is 10.9% down from 4.0 million last month.
There are a few different ways that this level of interest in shorting Genpact shares can be evaluated.
Genpact's "short interest ratio" (SIR) is the quantity of Genpact shares currently shorted divided by the average quantity of Genpact shares traded daily (recently around 742758.66388309). Genpact's SIR currently stands at 4.79. In other words for every 100,000 Genpact shares traded daily on the market, roughly 4790 shares are currently held short.
However Genpact's short interest can also be evaluated against the total number of Genpact shares, or, against the total number of tradable Genpact shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Genpact's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Genpact shares in existence, roughly 20 shares are currently held short) or 0.0205% of the tradable shares (for every 100,000 tradable Genpact shares, roughly 21 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Genpact.
Find out more about how you can short Genpact stock.
Dividend payout ratio: 18.1% of net profits
Recently Genpact has paid out, on average, around 18.1% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.87% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Genpact shareholders could enjoy a 0.87% return on their shares, in the form of dividend payments. In Genpact's case, that would currently equate to about $0.41 per share.
While Genpact's payout ratio might seem low, this can signify that Genpact is investing more in its future growth.
Genpact's most recent dividend payout was on 23 September 2021. The latest dividend was paid out to all shareholders who bought their shares by 8 September 2021 (the "ex-dividend date").
Over the last 12 months, Genpact's shares have ranged in value from as little as $33.59 up to $52.6399. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Genpact's is 1.427. This would suggest that Genpact's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Genpact Limited provides business process outsourcing and information technology (IT) services North and Latin America, India, rest of Asia, and Europe. It operates in three segments: Banking, Capital Markets and Insurance; Consumer Goods, Retail, Life Sciences and Healthcare; and High Tech, Manufacturing and Services. The company's finance and accounting services include accounts payable, such as document management, invoice processing, approval and resolution management, and travel and expense processing; invoice-to-cash services, including customer master data management, credit and contract management, fulfillment, billing, collections, and dispute management services; record to report services comprising accounting, treasury, tax, product cost accounting, and closing and reporting services; financial planning and analysis consisting of budgeting, forecasting, and business performance reporting; and enterprise risk and compliance services, including operational risks and controls. It also provides supply chain design, planning, inventory optimization, transportation and logistics management, and after-sales services; sourcing and procurement services comprising direct and indirect strategic sourcing, category management, spend analytics, procurement operation, master data management, and other procurement and supply chain advisory services; and sales and commercial services in the lead-to-quote, quote-to-order, and customer service areas. In addition, the company offers IT services, which include end-user computing support, infrastructure management, application production support, and database management services; and transformation services that include digital solutions, consulting services, and analytics services and solutions. It serves banking, capital market, insurance, consumer goods, retail, life science, healthcare, high tech, and manufacturing and service industries. Genpact Limited was founded in 1997 and is based in Hamilton, Bermuda.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.